We are live on ! Find out more
LOGC

LogicBio Therapeutics, Inc. Common Stock
LOGC

Delisted

LOGC was delisted on the 15th of November, 2022.

Back to rankings

0 hedge funds and large institutions have $0 invested in LogicBio Therapeutics, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 39 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 39 → 0 (-39)

100% less capital invested

Capital invested by funds: $513K → $0 (-$513K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 39

Holders
–
Holders Change
-39
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
39
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$136K
2
Renaissance Technologies
Renaissance Technologies
New York
-$77K
3
BlackRock
BlackRock
New York
-$47K
4
BBA
Baker Bros. Advisors
New York
-$38K
5
Geode Capital Management
Geode Capital Management
Massachusetts
-$37K
Name Holding Trade Value Shares
Change 		Change in
Stake
BNP Paribas Financial Markets
26
BNP Paribas Financial Markets
France
– -$69 -252 Closed
1
2

LOGC Hedge Fund Activity: Q4 2022 in Review

0 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in LogicBio Therapeutics, Inc. Common Stock (LOGC) for Q4 2022, worth a combined $0 — down 100% from $513K a quarter earlier.

Sellers outnumbered buyers: 39 funds closed out of LOGC and 0 opened new positions — a net loss of 39 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Vanguard Group, exiting entirely with an estimated $136K sold.

  • 0 institutional investors held LogicBio Therapeutics, Inc. Common Stock (LOGC) as of Q4 2022, down from 39 in Q3 2022.
  • Funds reported $0 of LogicBio Therapeutics, Inc. Common Stock stock for Q4 2022, down 100% quarter-over-quarter.
  • 0 funds opened new LogicBio Therapeutics, Inc. Common Stock positions in Q4 2022 and 39 closed out, a net change of -39 holders.
  • The largest LogicBio Therapeutics, Inc. Common Stock seller in Q4 2022 was Vanguard Group, an estimated $136K sold.

Based on aggregated 13F filings for Q4 2022.